Lv5
822 积分 2025-11-11 加入
Carvedilol as the new non‐selective beta‐blocker of choice in patients with cirrhosis and portal hypertension
1个月前
已完结
The intestinal barrier: a pivotal role in health, inflammation, and cancer
1个月前
已完结
Gut-liver axis: Pathophysiological concepts and clinical implications
1个月前
已完结
Interaction of inflammation and portal hypertension in cirrhosis progression
1个月前
已完结
Role of Toll-Like Receptors in Immune Activation and Tolerance in the Liver
1个月前
已完结
Interleukin‐1 and inflammasomes in alcoholic liver disease/acute alcoholic hepatitis and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
1个月前
已完结
The gut-liver axis in liver disease: Pathophysiological basis for therapy
1个月前
已完结
Fecal microbiota transplantation in alcohol-associated acute-on-chronic liver failure: an open-label clinical trial
2个月前
已完结
Microbiota transplant for hepatic encephalopathy in cirrhosis: The THEMATIC trial
2个月前
已完结
Fecal microbiota transplantation alleviates cirrhotic portal hypertension in rats via butyrate-mediated HDAC3 inhibition and PI3K/Akt/eNOS signaling regulation
2个月前
已完结
皖公网安备34019202002308
